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Abstract
K-ras is the most commonly mutated oncogene in pancreatic cancer and its activation in murine
models is sufficient to recapitulate the spectrum of lesions seen in human pancreatic ductal
adenocarcinoma (PDAC). Recent studies suggest that Notch receptor signaling becomes reactivated
in a subset of PDACs, leading to the hypothesis that Notch1 functions as an oncogene in this setting.
To determine whether Notch1 is required for K-ras-induced tumorigenesis, we employed a mouse
model in which an oncogenic allele of K-ras is activated and Notch1 is deleted simultaneously in the
pancreas. Unexpectedly, the loss of Notch1 in this model resulted in increased tumor incidence and
progression implying that Notch1 can function as a tumor suppressor gene in PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of human
cancer. Pathogenesis of PDAC is thought to evolve through progression of precursor lesions,
termed pancreatic intraepithelial neoplasias (PanINs). The PanINs are classified into four
subgroups (1A, 1B, 2, and 3) and eventually evolve into invasive carcinoma. The most
commonly mutated oncogene in PDAC is K-ras, with activating mutations found in more than
90% of human cases. Recently developed animal models have further underscored this point,
as expression of a mutant activated K-ras allele in the pancreas is sufficient to induce the
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formation of both pre-malignant and malignant lesions in a mouse model, faithfully
recapitulating the human disease (1).
Recent studies have implicated Notch1 as a potential oncogene in PDAC, as Notch targets
appear to become reactivated in a subset of PanINs and PDAC (1-3). The Notch proteins are
central components of pancreatic development and are required for directing cell fate decisions
and proliferation (4,5). While Notch1 was originally identified as an oncogene, recent evidence
indicates that Notch1 can also function as a tumor suppressor (6). Conclusive evidence comes
from studies in the skin, where loss of both Notch1 alleles led to development of basal cell
carcinoma (7) by mechanisms impacting the tumor microenvironment (8).
Notch and Ras have been shown to cooperate or antagonize one another in a manner that is
dependent upon cellular context (9). Previous studies have suggested that the ability of Ras to
transform cells depends upon Notch function (10,11). In the case of PDAC, it has been recently
shown that ectopic expression of activated Notch1 and K-ras in the mouse pancreas synergizes
in inducing PanIN formation (12). Thus, we hypothesized that K-ras and Notch1 functions
intersect specifically in the pathogenesis of PDAC. To test this directly, in vivo, we generated
a compound mutant mouse where K-ras is activated and Notch1 deleted simultaneously in the
pancreas. Surprisingly, we found that this resulted in increased tumor incidence and




The LSL-KrasG12D (13), Notch1lox/lox (14) and PDX-1-Cre (1) mice have been previously
described.
KrasG12D and Notch1 allele recombination PCR assays
KrasG12D allele was analyzed by PCR as described (13). Notch1 allele recombination PCR
assay was performed as described, without multiplexing (15).
Histology and immunohistochemistry
Formalin-fixed paraffin embedded murine pancreatic tissue was processed by standard
methods, or subject to immunohistochemical staining, using citrate buffer antigen retrieval.
Antibodies: Rat anti-Ki67, (1:400, Dako); rabbit anti-cleaved caspase-3 (1:200, Cell
Signaling); rabbit anti-Hey1, (1:125, Abcam); rabbit anti-Hes1 (1:500, B. Stanger, U.
Pennsylvania), mouse anti-β-catenin (1:200, BD Biosciences).
Quantitative PCR
Pancreatic tissue samples were snap-frozen. Total RNA was isolated using the Nucleospin
RNA II kit (Macherey-Nagel) and reverse transcribed using Superscript II Reverse
Transcriptase (Invitrogen). cDNA transcripts were amplified by quantitative real-time PCR
using SYBR Green (Applied Biosystems). Detection/quantitation done on ABI Prism 7000
(Applied Biosystems). Each gene was normalized to 18S rRNA. Notch1 primer sequences:
Fwd–TGGATGTCAATGTTCGAGGA, Rev-CACTGCAGGAGGCAATCAT.
Western blot analysis
Tissues/cells were homogenized in RIPA buffer. Primary antibodies: rabbit anti-Notch1
(1:500, Epitomics), rabbit anti-Notch2, 3 and 4 (all 1:200, Santa Cruz), mouse anti-β-catenin
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(1:1000, BD Biosciences), mouse anti-active β-catenin (1:1000, Millipore), rabbit anti-
GAPDH (1:10,000, Sigma) and mouse anti-tubulin (1:8000, Sigma).
Isolation and culture of primary pancreatic ductal cells
Primary pancreatic ductal cells (PDCs) were derived as previously described (16). For siRNA
experiments, PDX-1-Cre:KrasG12D:Notch1lox/lox PDCs were plated at 1×104 cells/well in a
12 well plate on day -1, transfected on day 0 with either β-catenin ON-TARGETplus SMART
pool siRNA or ON-TARGETplus Non-targeting siRNA pool#3 (Dharmacon), using
DharmaFect 2 transfection reagent (Dharmacon) following the manufacturers protocol.
Statistical Analysis
Ki67 positive nuclei comparisons were assessed by a standard unpaired t-test. Error bars
represent the standard deviation of triplicate counts (p value ≤ 0.05 was considered significant).
For real time PCR, mean ± standard deviation are shown.
Results and discussion
Loss of Notch1 in the context of activated K-ras leads to increased PanIN incidence and
progression
To test whether Notch1 is required for K-ras-induced pancreatic tumorigenesis in vivo, we
employed a mouse model of PDAC (1). The simultaneous expression of an oncogenic K-ras
allele and deletion of both Notch1 alleles was achieved by interbreeding mice harboring both
a conditional activated K-ras allele (LSL-K-rasG12D) (13) and conditional Notch1lox/lox
knockout alleles (14) with PDX-1-Cre transgenic mice that express Cre-recombinase as early
as day 8.5 of embryonic development in progenitors of all major pancreatic cell types (17).
We compared the pancreata of Pdx1-Cre:LSL-K-rasG12D:Notch1lox/lox mice to those of Pdx1-
Cre:LSL-K-rasG12D mice. At a 20-week time point, the PDX-1-Cre:LSL-K-rasG12D pancreata
displayed predominantly a combination of very early changes; acinar to ductal metaplasia
(ADM), tubular complexes (TC) and PanIN1A lesions (Fig. 1A). Approximately 50% of the
mice displayed ADM/TC, 30% displayed PanIN1A and less than 20% displayed a lesion
classified as PanIN1B (Fig. 2A), consistent with previous findings in this model (1). In contrast,
100% of PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox pancreata were classified histologically as
PanIN1B, transitioning to PanIN2 (Fig. 1A and 2A). All mice in this cohort displayed tissue
architecture that was significantly altered. The majority of ducts exhibited PanIN1B-PanIN2
changes, with only between 10-40% of normal acinar, ductal and islet tissue remaining (Fig.
1B-D and 2A). The appearance of intraepithelial and stromal polymorphonuclear leukocytes
(PMNs), a cell type often present in subtypes of human pancreatic cancer and thought to play
a role in carcinogenesis, was noted (Fig. 1D). Thus, the PDX-1-Cre:LSL-K-
rasG12D:Notch1lox/lox mice displayed both increased numbers and more advanced stage PanIN
lesions than the PDX-1-Cre:LSL-K-rasG12D mice. The PDX-1-Cre:Notch1lox/lox pancreata
displayed no signs of abnormalities (Fig. 1A and 2A), consistent with recently published
findings (18). Likewise, PDX-1-Cre pancreata appeared unremarkable (not shown). To verify
the expected Cre-mediated recombination events occurred, we isolated genomic DNA from
the pancreata and tails of mice from the various genotypes and performed PCR reactions to
monitor recombination events. DNA isolated from the pancreas, and not the tails, verified
recombination of both alleles (Supp. Fig. 1).
Additionally, mice that are heterozygous for the floxed Notch1 allele (Pdx1-Cre:LSL-K-
rasG12D:Notch1lox/+) exhibited an intermediate phenotype. PanIN lesions were predominantly
graded as PanIN1B, but a much greater proportion of normal acinar, ductal and islet tissue
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remained than when compared to the PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox cohort (not
shown).
To compare the proliferative index of the pre-neoplastic lesions in the PDX-1-Cre:LSL-K-
rasG12D and PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox pancreata, we performed Ki67
immunohistochemical staining and scored the number of positive cells per duct (Fig. 2B). Ki67
positive nuclei were more frequent in similar grade PanINs from PDX-1-Cre:LSL-K-
rasG12D:Notch1lox/lox pancreata compared to PDX-1-Cre:LSL-K-rasG12D pancreata (Fig. 2C).
This indicates that in similar grade lesions more cells were actively proliferating in the PDX-1-
Cre:LSL-K-rasG12D:Notch1lox/lox pancreata. To rule out that decreased rates of apoptosis lead
to a more severe phenotype in PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox, we stained sections
for cleaved caspase-3. No difference was evident when compared to PDX-1-Cre:LSL-K-
rasG12D pancreata (Fig. 2D). These studies demonstrate that the loss of Notch1 in the context
of activated K-ras results in increased proliferation rates of pancreatic ductal cells in vivo,
increased PanIN incidence, and progression. This implies that Notch1 possesses tumor
suppressor-like function in a mouse model of Kras-induced PDAC.
In a recent report, conditionally co-expressing activated Notch and K-ras in mouse pancreata
induced synergy in PanIN formation (12). This was interpreted as an indication of Notch1
functioning to inhibit the normal differentiation of the tumor initiating cells in the pancreas. It
is possible that differences in target cells and/or timing of recombination events might account
for the differences between our findings. In addition, Notch1 expression and activation are
highly regulated and overexpression of a constitutively active form of Notch1 could lead to
non-physiological phenomena. Finally, a recent report which catalogued core signaling
pathways in human pancreatic cancer suggests that the expression levels of Notch-family
members and downstream targets were not up-regulated in primary tumor samples and cell
lines, when compared to normal pancreatic ductal epithelium (19).
Activation of Notch family members is not responsible for accelerated tumorigenesis in
PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox mice
To assess whether other Notch family members (Notch 2- 4) are induced to compensate and
substitute for the loss of Notch1, we examined the expression and activation of the Notch family
receptors. Employing quantitative PCR to verify loss of Notch1 expression we find, as
expected, that expression of Notch1 mRNA was reduced in both the PDX-1-
Cre:Notch1lox/lox and PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox pancreata, when compared to
control PDX-1-Cre pancreata. In the PDX-1-Cre:LSL-K-rasG12D pancreata the expression of
Notch1 mRNA appeared to be slightly upregulated when compared to PDX-1-Cre (Fig. 3A).
Additionally, we analyzed Notch1 protein levels by western blotting, confirming loss of Notch1
in PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox and PDX-1-Cre:Notch1lox/lox pancreata (Fig. 3B).
Western blot analysis of Notch2, 3 and 4, in extracts prepared from pancreas tissue, as above,
indicates no significant differences in levels of expression between the cohorts (Fig. 3C). To
further establish whether the activity of Notch family members might be increased in the
pancreas of PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox mice we analyzed the expression of
established Notch downstream target genes, Hes1 and Hey1, by immunohistochemistry.
Expression of Hes1 and Hey1 was detected at similar levels in comparable grade lesions of
PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox mice compared to PDX-1-Cre:LSL-K-rasG12D (Fig.
3D). Collectively our data indicate that Notch1 has been effectively deleted in the pancreas of
PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox mice, and that activation of other Notch family
members is not likely to account for the observed acceleration of tumorigenesis in these mice.
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Activation of β-catenin in pancreata of PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox mice
To investigate potential mechanisms underlying the observed tumor suppressive function of
Notch1 in K-ras-induced PDA, we examined the status of β-catenin, which has been identified
as a target of Notch1's tumor suppressor function in the skin (4,7). In normal adult pancreas,
localization at the cell membrane serves as an indication of inactivity while both cytoplasmic
and nuclear localization of β-catenin are commonly regarded as indicators of active canonical
Wnt/β-catenin signaling (20). In PDX-1-Cre acinar and ductal cells, total β-catenin was
restricted to the cell membrane (Fig. 4A). In PDX-1-Cre:LSL-K-rasG12D β-catenin was
observed mostly in ductal cells at the cell membrane and faintly in the cytoplasm (Fig. 4A). In
contrast, intense β-catenin staining was observed in the membrane and cytoplasm in PDX-1-
Cre:LSL-K-rasG12D:Notch1lox/lox ductal cells, implying β-catenin levels are induced and
possibly activated (Fig. 4A). Importantly, total β-catenin levels were similar in pancreatic cells
of all genotypes (Fig. 4B).
To further assess β-catenin activation directly in pancreatic ductal cells, we isolated primary
pancreatic ductal cells (PDCs) from each of the different genotypes. Western blot analysis
revealed no increase in either total or activated β-catenin (dephosphorylated on Ser37 and
Thr41) in PDCs derived from PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox mice compared to the
other genotypes (Fig. 4C). Finally, in order to functionally determine if β-catenin is required
for proliferation of PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox PDCs, β-catenin was knocked
down in these cells using an siRNA-based approach. Cells treated with β-catenin siRNA
displayed a significant reduction in β-catenin levels, however this knockdown did not effect
the proliferative capacity of these cells, when compared to untreated cells or cells treated with
non-targeting siRNA (Fig. 4D).
These findings suggest that β-catenin repression might not represent the putative tumor
suppressive function of Notch1 in our mouse model of K-ras-induced PDAC. This conclusion
is based on studies in PDCs and it is possible that these findings do not reflect the complex
interactions occurring in vivo.
In conclusion, we show that loss of Notch1, in the context of activated K-ras, leads to
acceleration of tumor progression and an increase in PanIN numbers in a mouse model of
PDAC. This implies that Notch1 can function as a tumor suppressor in K-ras-induced PDAC
and additional studies are required to determine which downstream effectors of Notch1
signaling are essential for this activity.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Histological analysis of pancreata
(A) H&E stained sections from pancreata at 20 weeks of PDX-1-Cre:Notch1lox/lox mice (i =
islet), PDX-1-Cre:LSL-K-rasG12D mice (arrowhead = tubular complexes-TC), and PDX-1-
Cre:LSL-K-rasG12D:Notch1lox/lox mice (arrows = ducts exhibiting PanIN 1B-2 changes). Scale
bar = 400μm. (B-D) Detailed characterization of pathology exhibited in PDX-1-Cre:LSL-K-
rasG12D:Notch1lox/lox pancreata. (B) PanIN1B; papillary ductal lesions without significant loss
of polarity or nuclear atypia (arrows). (C) PanIN1B transiting to PanIN2 revealing moderate
nuclear atypia and a loss of polarity. (D) PanIN1B showing intraepithelial polymorphonuclear
leukocytes (arrowheads). Scale bar = 200μm.
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Figure 2. Characterization of pancreatic pathology in the experimental cohorts
(A) Grouped illustration of predominant pancreatic pathology in each of the four experimental
cohorts at 20 weeks; NAD – no abnormality detected, ADM/TC – acinar to ductal metaplasia/
tubular complexes, PanINs – pancreatic intraepithelial neoplasias. N=10 animals from each
cohort (B) Representative Ki67 staining in PDX-1-Cre:LSL-K-rasG12D and PDX-1-Cre:LSL-
K-rasG12D:Notch1lox/lox pancreata. Arrowheads point to Ki67 positive nuclei. Scale bar =
80μm. (C) Number of Ki67 positive nuclei per PanIN lesion in pancreata from PDX-1-
Cre:LSL-K-rasG12D (PK) and PDX-1-Cre:LSL-K-rasG12D:Notch1lox/lox (PKN) mice. Six
pancreata from each genotype were analyzed; 100 PanINs per pancreata were counted. (D)
Representative cleaved caspase-3 staining in PDX-1-Cre:LSL-K-rasG12D and PDX-1-
Cre:LSL-K-rasG12D:Notch1lox/lox pancreata. Scale bar = 80 μm.
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Figure 3. Expression of Notch family members and targets in pancreata from cohorts
(A) Relative expression levels of Notch1 in pancreatic tissue determined by qPCR (normalized
to 18srRNA). (B) Western blot analysis of Notch1 in whole pancreatic lysates. Both the full
length Notch1 (250kDa) and cleaved Notch1 intracellular domain (120kDa) are detected. Three
independent samples are shown for each genotype. PKN=PDX-1-Cre:LSL-K-
rasG12D:Notch1lox/lox, PK=PDX-1-Cre:LSL-K-rasG12D, PN=PDX-1-Cre:Notch1lox/lox,
P=PDX-1-Cre. (GAPDH =loading control). (C) Expression of Notch 2, 3, and 4 in whole
pancreatic lysate determined by western blot analysis. Three independent samples are shown
for each genotype. (GAPDH =loading control). (D) Immunohistochemical analysis of Hes1
and Hey1 in similar grade PanIN lesions. Scale bar = 40μm.
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Figure 4. Expression and activation state of β-catenin in pancreata from cohorts
Expression and localization of total β-catenin (A) (Scale bar = 40μm) by immunohistochemical
staining in pancreata from PDX-1-Cre, PDX-1-Cre:LSL-K-rasG12D, and PDX-1-Cre:LSL-K-
rasG12D:Notch1lox/lox mice. (B) Expression levels of total β-catenin in whole pancreatic lysates
by western blot analyses. Four independent samples are shown for PDX-1-Cre:LSL-K-
rasG12D:Notch1lox/lox (PKN) and PDX-1-Cre:LSL-K-rasG12D (PK) cells, 3 independent
samples for PDX-1-Cre:Notch1lox/lox (PN) cells and 2 independent samples forPDX-1-Cre
(P) cells. (GAPDH = loading control). (C) Western blot analysis of total and activated β-catenin
expression in PDCs. (Tubulin = loading control). Results shown are representative of two
independent PDC lines tested for each genotype. (D) Proliferation of PDX-1-Cre:LSL-
KrasG12D:Notch1lox/lox PDCs untreated, treated with Non-targeting siRNA pool (Ntg siRNA),
or β-catenin siRNA pool (β-cat siRNA). Values shown are the mean of 3 independent samples.
Western blot analysis of β-catenin knockdown in PDCs treated with siRNA on days 2, 3, and
4. (Tubulin =loading control).
Hanlon et al. Page 10
Cancer Res. Author manuscript; available in PMC 2011 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
